We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity Launches Signals AI to Advance Scientific R&D Workflows
Read MoreHide Full Article
Key Takeaways
Revvity launched Signals AI, a native agentic framework embedded in its Signals One platform.
RVTY shares fell 1% after the news, but the stock has outperformed its industry year to date.
Signals AI lets researchers use natural language to explore data, workflows and scientific knowledge.
Revvity, Inc. (RVTY - Free Report) recently announced the expansion of artificial intelligence capabilities across its Signals software business with the launch of Signals AI, a native agentic framework embedded within the Signals One platform. Designed to help scientists navigate complex R&D environments, Signals AI enables researchers to interact with connected scientific data, knowledge and workflows using natural language.
Rather than simply collecting information, Signals AI helps scientists transform large volumes of experimental, instrument, application and system-generated data into meaningful insights, informed decisions and actionable outcomes.
Per management, the addition of Signals AI to the Signals One platform represents a significant shift in how scientists interact with R&D knowledge. For many years, scientific software has organized information through predefined applications, workflows and dashboards. Signals AI introduces a new model, enabling researchers to access organizational knowledge directly, ask questions in natural language and dynamically transform information based on their needs. By combining the reasoning of modern AI with trusted scientific intelligence, management believes Signals AI can help organizations accelerate insight without compromising scientific rigor.
Likely Trend of RVTY Stock Following the News
Following the announcement, RVTY shares dropped 1% at yesterday’s closing. In the year-to-date period, shares of the company gained 2.3% against the industry’s 7.8% decline. The S&P 500 has risen 8.9% in the same timeframe.
The launch of Signals AI is expected to strengthen Revvity’s position in the growing market for AI-powered scientific software and research informatics solutions. The ability to integrate natural language interactions into scientific workflows may increase adoption among research organizations seeking to improve productivity and innovation. The expansion of AI capabilities within the Signals One platform is likely to enhance Revvity’s competitive position and support the company’s long-term software growth strategy.
RVTY currently has a market capitalization of $11.16 billion.
Image Source: Zacks Investment Research
More on the News
Signals AI acts as an intelligence layer across the Signals One ecosystem, allowing researchers to search, understand and repurpose scientific knowledge dynamically based on their specific needs. By leveraging structured scientific data, domain-specific ontologies and validated scientific algorithms, the platform delivers scientifically relevant, traceable and context-aware responses.
Scientists can explore and analyze molecules, biological sequences, experimental results and interconnected research knowledge through interactive views, helping them validate findings and maintain scientific rigor throughout the research process.
With these capabilities, Signals AI helps transform scientific software from a system of record into a system of scientific understanding, enabling researchers to move from data to insight and from insight to action more efficiently. Select Signals AI capabilities are currently available, with additional enhancements expected in the coming weeks.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the AI in the life science analytics market is valued at $2.73 billion in 2026 and is expected to witness a CAGR of 10.8% through 2035.
Factors like the growing volumes of life sciences data, advancements in AI and machine learning technologies, rising adoption in drug discovery and precision medicine and increasing healthcare digitization and industry support are boosting the market’s growth.
Other News
In May, Revvity exited the first quarter of 2026 with earnings and revenues surpassing estimates. Top-line performance benefited from growth in Life Sciences, driven by demand in pharma/biotech and academic/government markets, alongside strength in Diagnostics led by reproductive health testing. During the quarter, Revvity continued investing in innovation through the launch of Signals BioDesign software and the Opera Phenix OptiQ high-content screening system, reinforcing its focus on expanding long-term growth opportunities.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
View the Zacks #1 Rank List
Image: Bigstock
Revvity Launches Signals AI to Advance Scientific R&D Workflows
Key Takeaways
Revvity, Inc. (RVTY - Free Report) recently announced the expansion of artificial intelligence capabilities across its Signals software business with the launch of Signals AI, a native agentic framework embedded within the Signals One platform. Designed to help scientists navigate complex R&D environments, Signals AI enables researchers to interact with connected scientific data, knowledge and workflows using natural language.
Rather than simply collecting information, Signals AI helps scientists transform large volumes of experimental, instrument, application and system-generated data into meaningful insights, informed decisions and actionable outcomes.
Per management, the addition of Signals AI to the Signals One platform represents a significant shift in how scientists interact with R&D knowledge. For many years, scientific software has organized information through predefined applications, workflows and dashboards. Signals AI introduces a new model, enabling researchers to access organizational knowledge directly, ask questions in natural language and dynamically transform information based on their needs. By combining the reasoning of modern AI with trusted scientific intelligence, management believes Signals AI can help organizations accelerate insight without compromising scientific rigor.
Likely Trend of RVTY Stock Following the News
Following the announcement, RVTY shares dropped 1% at yesterday’s closing. In the year-to-date period, shares of the company gained 2.3% against the industry’s 7.8% decline. The S&P 500 has risen 8.9% in the same timeframe.
The launch of Signals AI is expected to strengthen Revvity’s position in the growing market for AI-powered scientific software and research informatics solutions. The ability to integrate natural language interactions into scientific workflows may increase adoption among research organizations seeking to improve productivity and innovation. The expansion of AI capabilities within the Signals One platform is likely to enhance Revvity’s competitive position and support the company’s long-term software growth strategy.
RVTY currently has a market capitalization of $11.16 billion.
Image Source: Zacks Investment Research
More on the News
Signals AI acts as an intelligence layer across the Signals One ecosystem, allowing researchers to search, understand and repurpose scientific knowledge dynamically based on their specific needs. By leveraging structured scientific data, domain-specific ontologies and validated scientific algorithms, the platform delivers scientifically relevant, traceable and context-aware responses.
Scientists can explore and analyze molecules, biological sequences, experimental results and interconnected research knowledge through interactive views, helping them validate findings and maintain scientific rigor throughout the research process.
With these capabilities, Signals AI helps transform scientific software from a system of record into a system of scientific understanding, enabling researchers to move from data to insight and from insight to action more efficiently. Select Signals AI capabilities are currently available, with additional enhancements expected in the coming weeks.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the AI in the life science analytics market is valued at $2.73 billion in 2026 and is expected to witness a CAGR of 10.8% through 2035.
Factors like the growing volumes of life sciences data, advancements in AI and machine learning technologies, rising adoption in drug discovery and precision medicine and increasing healthcare digitization and industry support are boosting the market’s growth.
Other News
In May, Revvity exited the first quarter of 2026 with earnings and revenues surpassing estimates. Top-line performance benefited from growth in Life Sciences, driven by demand in pharma/biotech and academic/government markets, alongside strength in Diagnostics led by reproductive health testing. During the quarter, Revvity continued investing in innovation through the launch of Signals BioDesign software and the Opera Phenix OptiQ high-content screening system, reinforcing its focus on expanding long-term growth opportunities.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Key Picks
Revvity currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.